DLR Kredit A/S
Andre oplysningsforpligtelser offentliggjort efter børsens regler
DLR Kredit har fastsat kuponrenter for perioden 1. oktober 2026 til 4. januar 2027
på følgende Senior Non-Preferred Notes (SEK og NOK):
| ISIN | Navn | Referencerente | NyRente |
| DK0030576079 | SNP SEK July 2030 | STIBOR3M | 3,183% |
| NO0013754481 | SNP NOK July 2030 | NIBOR3M | 5,890% |
Spørgsmål kan rettes til Fonds og Funding, fonds@dlr.dk eller pr. tlf 33 42 07 38
Med venlig hilsen
DLR Kredit
Attachment
Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE®, an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI)
DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that its Chief Medical Officer, Kevin Chung, M.D., will deliver an invited talk at the 2026 PPETS conference, hosted by Texas Children’s Hospital in Houston, Texas, October 6 – 8, 2026.
The annual PPETS conference gathers leading international pediatric nephrologists, intensivists, neonatologists, and extracorporeal therapy specialists to share innovations in pediatric continuous renal replacement therapy (CRRT), extracorporeal membrane oxygenation (ECMO), and related therapies. It addresses practice variation, emerging technologies, and evidence gaps through expert-led sessions, case discussions, and simulation-based training.
“I’m grateful to the PPETS organizers for the opportunity to participate in this important meeting,” said Dr. Chung. “I look forward to sharing lessons from our experience with QUELIMMUNE and discussing what we’ve learned about translating medical innovation into delivering improved outcomes to the most vulnerable patients.”
Dr. Chung’s presentation will highlight lessons learned in medical device innovation, using QUELIMMUNE as an example of the journey, from identifying an unmet clinical need to bringing a new therapy to the bedside. He is one of four presenters at the following session that also includes a session by James Odum, M.D., Pediatric Critical Care Medicine, Children’s Hospital of Alabama, regarding the use of SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy:
The Future of Pediatric Extracorporeal Therapies Innovation, Emerging Technologies, and the Next Generation of Support
Date & Time: Tuesday, October 6, 2026, 8:30 am to 10:00 am CDT
Presentations Include:
Dynamic renal monitoring: Are Daily Serum Creatinine a Thing of The Past?
Stuart Goldstein, M.D., Director, Center for Acute Care Nephrology, Cincinnati Children’s Hospital Medical Center
Endotoxin Removal: Reversing Triggers of Immune Dysregulation
John Kellum, M.D., Distinguished Professor of Critical Care Medicine, University of Pittsburgh School of Medicine
Taming Monocytes and Neutrophils: Reversing Severe AKI by Leveraging Selective Cytopheretic Devices
James Odum, M.D., Pediatric Critical Care Medicine, Children’s Hospital of Alabama at University of Alabama
Pipeline for Device Development: How to Support The Next Generation of Thinkers
Kevin Chung, M.D., Chief Medical Officer, SeaStar Medical
About QUELIMMUNE
The QUELIMMUNE® (SCD-PED) therapy is being commercialized for children with AKI and sepsis or septic condition weighing 10 kilograms or more who are on antibiotics and being treated in the ICU with RRT. It was approved in February 2024 under a Humanitarian Device Exemption application.
Data from two clinical trials of the QUELIMMUNE therapy, published in Kidney Medicine, showed a 77% survival rate in patient treated with QUELIMMUNE versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data in this patient population. No dialysis was required for survivors, and 87.5% of survivors had normal kidney function at Day 60 after ICU discharge. In February 2026, data published in the prestigious, peer-reviewed journal, Pediatric Nephrology, highlighted the early experience from the QUELIMMUNE SAVE Registry, a post-approval surveillance registry, evaluating the role of the QUELIMMUNE therapy in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring renal replacement therapy. Observations from the first 21 pediatric patients with AKI and sepsis requiring renal replacement therapy showed no device-related adverse events or infections and no reports of immunosuppressive effects by the device. In addition, preliminary outcomes analyses show a 76% survival rate at Day 28 and Day 60, and a 71% survival rate at Day 90. These new data are on track to validate a 50% reduction in patient mortality at 60 days compared to historical data, similar to what was observed in the registration study reported in Kidney Medicine.
The patented technology behind QUELIMMUNE is known as the Selective Cytopheretic Device (SCD) therapy and has broad applications for treating the destructive hyperinflammation that shuts down organ function and causes loss of life.
About the SeaStar Medical Selective Cytopheretic Device (SCD) Therapy
The SCD therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy is designed for broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing continuous RRT hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future continuous RRT, including dialysis, and prevent loss of life.
About NEUTRALIZE-AKI Pivotal Trial
The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomIZEd clinical trial in Acute Kidney Injury) pivotal trial is evaluating the safety and efficacy of the SCD therapy in 339 adults with AKI in the ICU receiving continuous RRT. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD therapy in addition to continuous RRT as the standard of care, compared with the control group receiving only continuous RRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of the SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome.
About Acute Kidney Injury (AKI) and Hyperinflammation
AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as severe infections or other septic conditions, severe trauma, surgery, and organ failures. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to commercial acceptance of QUELIMMUNE; the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
IR@SEASTARMED.COM
QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.
Following termination of ATM, Company has substantially utilized its shelf capacity
Company also strengthens Board with the addition of two seasoned mining directors
CHARLOTTE, N.C., Sept. 29, 2026 (GLOBE NEWSWIRE) — via IBN – Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML; FSE: HK6), a Greenland-focused mineral resource development company, today announced that it has raised over $17 million through a registered direct offering of common stock at a purchase price of $13.00 per share, bringing total capital raised by the Company over the past week to over $59 million. The financing materially strengthens the Company’s balance sheet and provides the capital required to execute its planned exploration and development programs and achieve its 2027 milestones across its Greenland portfolio. The financing substantially utilized the remaining capacity under the Company’s existing shelf registration statement.
The Company also announced the addition of Blair Jordan and Peter Love to its Board of Directors.
Mr. Jordan is an experienced public-company executive, director, investment banker and attorney who currently serves as Chief Executive Officer and a director of Tungsten Reserve Corp. and as an independent director and Chair of the Audit Committee of Standard Uranium Ltd. He previously served as Chief Executive Officer and a director of Forum Markets, Incorporated, where he led a restructuring and subsequently completed a $425 million private placement. Earlier in his career, he served as a Managing Director and Corporate Director of Ventum Financial and spent nearly a decade with Credit Suisse in principal investing, leveraged finance, restructuring, special situations and convertible bonds. He began his career as a securities lawyer with Bennett Jones LLP.
Mr. Love has more than 18 years of experience in mineral exploration and corporate finance for the natural-resources industry. He is Executive Chairman and co-founder of Torino Metals and previously co-founded Proximo Resources, which was acquired by Rugby Mining Limited, following which he served as a director and Chief Executive Officer of Rugby Mining. He also previously served as Chairman of Intrepid Mines Limited and Chairman of Talon Petroleum Limited.
About Greenland Mines Ltd
Greenland Mines Ltd is a Nasdaq-listed resource development and mining company focused on the development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and select midstream processing opportunities, while advancing its assets and broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “potential,” “could,” “may,” “will,” “should,” “estimate,” “objective” and similar expressions.
Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties. Many factors could cause actual results to differ materially, including exploration, resource-estimation, metallurgical, engineering, environmental, social, permitting, logistical, infrastructure, financing, commodity-price, market, counterparty and execution risks; changes to planned programs and timelines; the Company’s ability to obtain required approvals and financing; and risks described in documents filed or to be filed with the U.S. Securities and Exchange Commission. No assurance can be given that studies, applications, partnerships, transactions, development decisions or production will occur on the timing contemplated or at all.
Readers should carefully consider these factors and the other risks and uncertainties described in the Company’s SEC filings. All information in this press release is provided as of its date, and the Company undertakes no obligation to update any forward-looking statement except as required by applicable law.
Investor Contact and Corporate Communications:
ir@greenlandmines.com
Website: www.greenlandmines.com
Corporate Communications:
IBN
Austin, Texas
IBN.Ai
512.354.7000 Office
Editor@IBN.Ai
DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — Kraig Biocraft Laboratories (OTCQB: KBLB) reached a significant commercialization milestone, announcing the shipment of its first commercial order of recombinant spider silk yarn to a globally recognized performance sports brand. The custom-engineered yarn was produced to the customer’s specifications and is intended for development into a first-of-its-kind performance textile. While the shipment is small by design and part of a confidential pilot program, the significance is that Kraig’s material has moved beyond laboratory and scaled-production demonstrations into an actual customer development program targeting one of the most demanding segments of the textile market.
Kim Thompson, CEO and founder of Kraig Labs, described the delivery as “a huge milestone for Kraig Labs,” emphasizing that the project is designed around a precision application where spider silk’s combination of strength, flexibility, toughness and low weight can potentially provide differentiated performance. Thompson added, “High-performance sport is where materials prove themselves,” framing the customer program as an opportunity to demonstrate whether recombinant spider silk can translate its laboratory characteristics into a commercially relevant textile application.
The timing is notable against a massive global fiber market. Textile Exchange reported that worldwide fiber production reached a record 139 million metric tons in 2025, with polyester representing 59% of global production and 88% of polyester output coming from virgin fossil-based sources. Against that backdrop, new performance fibers face a dual challenge: demonstrating meaningful technical advantages while proving they can be produced consistently enough for commercial applications. Kraig has been pushing toward that scale, reporting more than 1.3 metric tons of spider silk cocoons produced in a single month earlier this year.
However, performance apparel is only one potential market for a material engineered around the unusual combination of strength, toughness, flexibility and low weight associated with spider silk. High-performance protective equipment, aerospace and aviation components, automotive materials, advanced composites, technical textiles, ropes and cables, filtration, medical devices and wound-care materials are among the broader categories that have attracted research interest in spider-silk-based materials. In medical applications, researchers have investigated spider silk proteins and fibers for areas including tissue engineering, drug delivery and wound-healing materials, while advanced-material researchers have explored their potential as components in lightweight composites and other high-performance structures.
Defense and protective applications represent another potentially important target because materials that combine low weight with strength and toughness can be valuable in applications where reducing weight without sacrificing performance is critical. Potential uses can include protective textiles, ballistic-related materials, technical fabrics and specialized load-bearing components. Automotive and aerospace applications similarly place a premium on lightweight materials that can withstand demanding mechanical environments. These are development opportunities rather than established commercial markets for Kraig, but they illustrate why the company’s strategy extends beyond conventional apparel.
Kraig’s commercial shipment also comes as its broader technology platform continues to advance. The company recently announced completion of its functional and living Atlas Gene Library, part of Project Atlas, which is designed to create new combinations of genetic elements and ultimately produce recombinant spider silk with customized performance characteristics. The company says the program is intended to expand strength, toughness and other properties, potentially allowing future fibers to be engineered around specific industrial, defense or commercial requirements. That ability to tune a fiber for a particular application could be especially important in advanced materials, where one customer may prioritize tensile strength while another could require elasticity, impact resistance, durability, lightweight construction or a combination of properties.
From a market perspective, the most compelling element is not simply that Kraig has shipped yarn, but that the company is beginning to test its material in a real-world product-development setting. Kraig previously reported testing showing that its commercially produced recombinant spider silk retained the strength and toughness demonstrated in earlier small-batch testing. National Geographic also recently spotlighted the company’s technology, including demonstrations in which Kraig’s silk was used to suspend a 170-pound tractor tire from a 0.35-ounce loop.
Thompson emphasized the significance of this order: “This is the kind of project that changes the conversation. When a brand at this level puts our material to the test, the results speak for themselves. We intend for this to be the first of many.”
The company is now attempting to bridge three increasingly important stages: production scale, customer validation and product integration. The first performance-brand shipment does not establish broad commercial adoption, recurring revenue or success in any of the other potential industries. Those applications would require additional development, customer validation and, in some cases, substantial regulatory and technical qualification.
The range of potential markets highlights the larger strategic opportunity: Kraig’s spider silk could potentially move from a novel textile material into a broader advanced-materials platform.
For Kraig Labs, Project Atlas adds another dimension to that opportunity. Rather than simply producing one standardized fiber, the company is pursuing the ability to develop increasingly specialized spider-silk materials tailored to specific performance requirements. If that approach succeeds, future generations could potentially be designed around greater strength, elasticity, toughness, lightweight construction or other characteristics demanded by particular customers and industries.
The first commercial shipment therefore represents more than a box of yarn leaving a production facility. It is an early confirmation that recombinant spider silk is transitioning from scientific achievement to customer-qualified material and potentially the first step toward much broader markets for engineered spider-silk technologies.
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/b530c2f4-3cc7-4beb-8af3-29eaf161525f
https://www.globenewswire.com/NewsRoom/AttachmentNg/ab979558-cd75-44fe-871b-5252d8888f89
BEIJING, Sept. 29, 2026 (GLOBE NEWSWIRE) — The All-China Federation of Industry and Commerce (ACFIC) has released the 2026 China Top 100 Private Service Enterprises list. Shandong Energy Chain Holding Co., Ltd., a subsidiary of Newlinks Technology Limited (“Newlinks”), the parent company of NaaS Technology Inc. (Nasdaq: NAAS) (“NaaS” or the “Company”), was named to the list at No. 85. The inclusion reflects the scale of Shandong Energy Chain Holding Co., Ltd.’s service business and comes as Newlinks continues to apply artificial intelligence (AI) to advance the digital and intelligent transformation of energy services.
In recent years, producer services, or services that support production and business operations, have played an increasingly important role in the economy and become a key area of service-sector development. This year, ACFIC conducted its 28th Survey of Large-Scale Private Enterprises, in which 6,350 enterprises with 2025 operating revenue above RMB 1 billion participated. Based on operating revenue, ACFIC separately ranked participating service-sector enterprises to compile the 2026 China Top 100 Private Service Enterprises list, providing a snapshot of the development of China’s modern service sector.
A New Model of Producer Services
Newlinks represents an emerging model of producer services in the transportation energy sector. Rather than relying primarily on ownership of energy assets, Newlinks connects supply and demand through digital platforms and data-driven services designed to improve energy replenishment efficiency, reduce unnecessary vehicle mileage and queuing time, and enhance station utilization. This asset-light approach creates value through connectivity, data and services rather than asset ownership, reflecting the broader evolution of the modern service economy.
With China’s new energy vehicle (NEV) fleet growing rapidly, this digital service model has expanded into the charging sector. Charging services face a highly fragmented supply side, with operators, stations and chargers owned and operated by different parties, making it difficult for any single enterprise to manage the full service chain, from charger discovery and charging to payment and settlement. NaaS acts as an industry connector through its charging platform and its relationships within Newlinks’ broader energy ecosystem. Newlinks’ gas station network provides site-selection experience that may inform charging station siting and the development of co-located fuel-and-charging stations. Long-standing relationships with automakers (OEMs) and fleet customers enable fueling and charging services to be jointly integrated into the smart cockpit systems of approximately 80% of China’s major automakers. The large volume of transaction data generated across both fueling and charging is used to train supply-and-demand matching algorithms and refine dispatch models. Together, these capabilities connect NaaS’ charging services with Newlinks’ broader energy digitalization ecosystem, supporting the development of NaaS’ charging service platform.
Making Better Use of Technology to Unlock the Value of Existing Charging Assets
Even as public charging infrastructure continues to expand, structural challenges remain, including uneven utilization across regions and the difficulty of achieving profitability from charging price spreads alone. The industry is shifting from rapidly building new chargers toward making better use of existing charging assets, with digitalization and AI-driven dispatch playing an increasingly important role in addressing these challenges. Against this backdrop, NaaS’ interconnection platform uses AI-powered supply-and-demand matching seek to improve operational efficiency for participants across the value chain.
By the end of 2025, NaaS’ charging platform covered 364 cities and had cumulatively connected approximately 50% of China’s public charging infrastructure, excluding dedicated chargers. In the first half of 2026, NaaS reported positive operating profit for the first time, marking an important milestone in the development of its asset-light digital charging service model.
From refined oil products to EV charging, Newlinks’ businesses have centered on a single aim: making energy replenishment more efficient. Shandong Energy Chain Holding Co., Ltd.’s inclusion in the Top 100 Private Service Enterprises list marks another milestone in the development of this service-focused model. NaaS will continue to serve as a connector and service platform for the charging industry. Drawing on its charging network and AI and digitalization capabilities, the Company will focus on real-world scenarios such as vehicle energy replenishment and station operations to seek to improve the energy replenishment experience and operating efficiency across the industry, supporting the green and low-carbon transition of transportation energy.
About NaaS Technology Inc.
NaaS Technology Inc. is the first U.S.-listed EV charging service company in China. The Company is a subsidiary of Newlinks, a leading energy digitalization group in China, and is one of the leading providers of new energy asset operation services. The Company uses advanced technology to intelligently match charging supply with demand, offering EV users a seamless, efficient and smart charging experience, while empowering charging stations and operators to optimize operations, improve efficiency and enhance profitability.
Safe Harbor Statement
This press release contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as “will,” “expects,” “believes,” “anticipates,” “intends,” “estimates” and similar statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. All information provided in this press release is as of the date hereof, and the Company undertakes no obligation to update any forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: NaaS’ goals and strategies; its future business development, financial condition and results of operations; its ability to continuously develop new technologies, services and products and keep pace with changes in the industries in which it operates; the growth of China’s EV charging industry and NaaS’ future business development; the demand for and market acceptance of NaaS’ products and services; NaaS’ ability to protect and enforce its intellectual property rights; NaaS’ ability to attract and retain qualified executives and personnel; fluctuations in the RMB exchange rate and NaaS’ ability to obtain adequate financing; NaaS’ relationships with end users, customers, suppliers and other business partners; competition in the industry; relevant government policies and regulations; and fluctuations in general economic and business conditions in China and globally. Further information regarding these and other risks is included in NaaS’ filings with the SEC.
For investor and media inquiries, please contact:
Investor Relations
NaaS Technology Inc.
E-mail: ir@enaas.com
Media inquiries:
E-mail: pr@enaas.com
President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening
Webinar to Be Held Wednesday, October 7, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open
GAITHERSBURG, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) — 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, October 7, 2026, at 12:00 p.m. Eastern time.
Jonathan Cohen, President and Chief Executive Officer of 20/20 BioLabs, will discuss the September 23, 2026 meeting of the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee and what management believes the panel’s deliberations may indicate for the broader multi-cancer early detection (“MCED”) category. Mr. Cohen will also discuss the Company’s newly introduced OneTest™ franchise model, preliminary interest from laboratories across the United States, and new state funding initiatives for firefighter cancer screening.
To access the webinar, please use the following information:
| Date: | Wednesday, October 7, 2026 |
| Time: | 12:00 p.m. Eastern time (9:00 a.m. Pacific time) |
| Webcast: | Please click here to register. |
During the webinar, management expects to address the following topics:
“The September 23 advisory committee meeting concerned another company’s test, but we believe many of the questions considered by the panel are relevant to multi-cancer early detection as a broader category,” said Jonathan Cohen, President and Chief Executive Officer of 20/20 BioLabs. “On October 7, I look forward to discussing what we believe the meeting may indicate about the regulatory path for MCED tests, where OneTest™ stands today, and how our new franchise model and growing firefighter screening programs could expand access to early cancer detection.”
The October 7 webinar is part of the Company’s monthly investor webinar series, held on the first Wednesday of each month at 12:00 p.m. Eastern time. Investors and other interested parties are encouraged to submit questions in advance to AIDX@mzgroup.us. A replay will be made available through the Company’s investor relations website following the event.
As part of its commitment to expanding access to early cancer detection, 20/20 BioLabs will provide webinar attendees with a promotional discount code for OneTest™ at the conclusion of the event. The offer will be available to all attendees, regardless of shareholder status.
Additional detail on the Company’s business, results of operations, and risk factors is available in its filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The webinar is not expected to include the disclosure of any material non-public information.
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection blood test and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s tests are designed to be affordable and accessible and can be conveniently utilized at home using new, upper-arm capillary collection devices as an alternative to traditional venipuncture. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
For more information visit https://2020biolabs.com.
Forward-Looking Statements
Certain statements in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, regulatory strategy, reimbursement strategy, growth strategy, acquisition strategy, and financial needs. Forward-looking statements can be identified by words such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project,” “continue,” or the negative of these terms or other comparable expressions.
Forward-looking statements in this release include, but are not limited to, statements regarding the Company’s planned investor webinar and the topics management expects to address. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including the risks described in the Company’s filings with the U.S. Securities and Exchange Commission.
There can be no assurance that the Company will complete any strategic transaction on any particular timeline, or at all. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events, except as required by applicable law.
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us
Orrön Energy AB (“Orrön Energy”) is pleased to announce the composition of the Nomination Committee for the 2027 Annual General Meeting (“AGM”) to be held on 14 April 2027.
The Nomination Committee has been formed with the following members:
At the Nomination Committee’s first meeting, Aksel Azrac was elected as Chair of the Nomination Committee.
The Nomination Committee shall make recommendations to the 2027 AGM regarding:
Shareholders who wish to present a motion to the Nomination Committee regarding the above-mentioned matters, should contact the Chair of the Nomination Committee, Aksel Azrac, at nomcom@orron.com no later than 31 December 2026.
For further information, please contact:
Robert Eriksson
Corporate Affairs and Investor Relations
Tel: +46 701 11 26 15
robert.eriksson@orron.com
Jenny Sandström
Communications Lead
Tel: +41 79 431 63 68
jenny.sandstrom@orron.com
Orrön Energy is an independent, publicly listed (Nasdaq Stockholm: “ORRON”) renewable energy and infrastructure company within the Lundin Group of Companies. The Company combines exposure to Nordic power markets and long-term cash flows from renewable power generation, with significant upside from a European development business comprising large-scale solar, battery, and data centre projects. With financial capacity to fund further growth and acquisitions, and backed by a major shareholder, management team and Board with a proven track record of investing into, leading and growing highly successful businesses, Orrön Energy is well positioned to create shareholder value through the energy transition.
Forward-looking statements
Statements in this press release relating to any future status or circumstances, including statements regarding future performance, growth and other trend projections, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipate”, “believe”, “expect”, “intend”, “plan”, “seek”, “will”, “would” or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that could occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to several factors, many of which are outside the company’s control. Any forward-looking statements in this press release speak only as of the date on which the statements are made and the company has no obligation (and undertakes no obligation) to update or revise any of them, whether as a result of new information, future events or otherwise.
Attachment
Positive weekly earnings and hours worked growth trends continue
ROCHESTER, N.Y., Sept. 29, 2026 (GLOBE NEWSWIRE) — According to the Paychex Small Business Employment Watch, which reports on employment levels in U.S. small businesses with fewer than 50 employees, the pace of job growth increased 0.02 percentage points to 99.15 in September. The jobs index remained broadly in line with the 2026 year-to-date average of 99.19. Hourly earnings growth remained below three percent in September (2.78%), extending a more than two-year trend of moderating wage growth. At the same time, weekly earnings and hours worked growth remained positive, indicating businesses continue to meet demand through existing workforce capacity.
“The small business labor market continues to demonstrate remarkable stability,” said John Gibson, Paychex president and CEO. “Our data shows businesses are largely maintaining staffing levels. The pace of employment growth across our overall client base improved slightly in September, with stronger growth among businesses with more than 50 employees. Sustained increases in weekly earnings and hours worked growth demonstrate that businesses continue to meet operational needs without increasing hiring. With hourly earnings growth remaining below three percent for more than two years, labor cost pressures have become more manageable. These trends point to a labor market that remains fundamentally solid.”
Jobs Index and Wage Data Highlights
About the Paychex Small Business Employment Watch
Since 2014, the Paychex Small Business Employment Watch has been a trusted source of employment trends for U.S. small businesses with fewer than 50 employees. The Employment Watch website offers interactive charts and historical data across the report’s two key components – the jobs index and wage data – as well as the methodology for both analyses. Visit the Bloomberg Terminals or subscribe to receive monthly alerts with the latest data.
*Information regarding the professions included in the industry data can be found at the Bureau of Labor Statistics website.
About Paychex
Paychex, Inc. (Nasdaq: PAYX) provides a comprehensive suite of expert-enabled technology and advisory solutions that help businesses manage HR, payroll, and benefits. Serving approximately 840,000 customers and paying 1 in 11 U.S. private sector workers, Paychex combines scale, trusted expertise, and innovation to help businesses succeed. Built on more than 50 years of workforce experience and one of the industry’s largest proprietary HR datasets, Paychex’s WISE agentic AI engine embeds intelligence directly into workflows to improve productivity, enhance decision-making, and deliver better outcomes. Learn more at paychex.com.
Media Contacts
Tracy Volkmann
Paychex, Inc.
Manager, Public Relations
(585) 387-6705
tvolkmann@paychex.com
Erin McAward
ICR, Inc.
Account Director
paychexpr@icrinc.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3545f218-10d1-412e-80d3-9e3960084691
Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients
ACCLARENT AERA® Eustachian Tube Balloon Dilation System
PRINCETON, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences (Nasdaq: IART), a leading global medical technology company, announced today the enrollment of the 100th patient in the AERA® Pediatric Registry, a prospective, multicenter observational registry evaluating the real-world clinical performance of the Acclarent AERA Eustachian Tube Balloon Dilation System in pediatric patients eight or older.
The milestone represents one-third of the registry’s planned enrollment of 300 patients and reflects the continued collaboration of participating investigators, research coordinators and clinical sites across the United States. Launched in July 2025, the registry is designed to generate real-world evidence regarding the use of AERA in children with obstructive Eustachian tube dysfunction, or ETD.
“Reaching the 100-patient milestone reflects meaningful progress in building real-world evidence in pediatric Eustachian tube dysfunction and its treatment,” said Christopher Schutt, M.D., vice president, Operations & Excellence, Office of the Chief Medical Officer, Integra LifeSciences. “We are grateful to the research teams and families whose participation is making this work possible. We are hopeful their contributions will help inform future clinical decision-making and advance understanding of care for children with ETD.”
ETD occurs when the Eustachian tube does not properly regulate pressure or drain fluid from the middle ear. The condition may contribute to symptoms including ear pressure or fullness, discomfort, hearing difficulties, and recurrent ear infections. Eustachian tube balloon dilation is a treatment option for appropriate patients with ETD.
“This milestone reinforces our commitment to the ear, nose, and throat (“ENT”) market and to advancing the evidence base supporting innovative treatment options for patients with Eustachian tube dysfunction,” said Harvinder Singh, executive vice president and president, Specialty Surgery, Integra LifeSciences. “We believe continued investment in clinical evidence generation is essential to supporting physicians, informing care decisions and strengthening our leadership position in ENT.”
AERA received FDA clearance for its pediatric indication in December 2023, becoming the first and only Eustachian Tube Balloon Dilation System indicated for pediatric patients ages eight and older.1
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.
About ACCLARENT AERA® Eustachian Tube Balloon Dilation System
The ACCLARENT AERA Eustachian Tube Balloon Dilation System is intended to dilate the Eustachian tube for treatment of persistent Eustachian tube dysfunction in patients ages 18 and older. For patients ages 8-17 years, the ACCLARENT AERA Eustachian Tube Balloon Dilation System, alone or in combination with adjunctive procedures, is intended to treat patients with objective signs of persistent obstructive Eustachian tube dysfunction from inflammatory pathology, resulting in chronic otitis media with effusion and are refractory to at least one surgical intervention for persistent obstructive Eustachian tube dysfunction.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections and involve inherent risks, assumptions and uncertainties that are difficult to predict and which may be beyond our control. Forward-looking statements that may be discussed include, but are not limited to, the potential clinical application and efficacy of the AERA Eustachian Tube Balloon Dilation System in pediatric patients, the number of patients expected to be involved in the AERA Pediatric Registry and the anticipated utility of data collected from the AERA Pediatric Registry. There can be no assurance that the AERA Pediatric Registry will be able to meet the enrollment and observation objectives described herein or that any potential clinical applications and benefits will be observed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Integra LifeSciences’s business, particularly those identified under the headings “Risk Factors” and “Special Note Regarding Forward-Looking Statements,” included in Integra LifeScience’s Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. The forward-looking statements included in this news release are made only as of the date of this news release and Integra LifeSciences undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
______________
1 U.S. Food and Drug Administration. ACCLARENT AERA Eustachian Tube Dilation System (K230742). Dec. 13, 2023. Website: FDA 510(k) Clearance Database – ACCLARENT AERA K230742 [accessdata.fda.gov]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4ef670f8-0782-4879-8f56-55f9ef15506a
CompuFlo Builds Momentum as Physician Adoption, Reimbursement Access, Commercial Coverage and Clinical Evidence Expand
ROSELAND, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE American: MLSS), a medical technology company specializing in advanced computerized injection and drug-delivery technologies, today highlighted continued progress in building a structured and scalable growth platform for its CompuFlo® medical business.
“We are building CompuFlo into a scalable medical business, and the early results are demonstrating the potential of that strategy,” said Eric Hines, Chief Executive Officer of Milestone Scientific. “Our growth in medical segment revenue reflects increasing market activity, while the expansion of our Advisor Program, reimbursement access, commercial organization and clinical footprint is creating the infrastructure to support much broader adoption. We are focused on converting physician experience into repeat utilization, expanding our presence in reimbursed markets and building the recurring disposable revenue model that can support sustained growth.”
Milestone has implemented a coordinated strategy centered on physician adoption, reimbursement, dedicated commercial execution, clinical support, market development and evidence generation. Together, these initiatives are designed to increase utilization, drive recurring disposable revenue and establish a repeatable model for geographic expansion.
Advisor Program Expanding Physician Experience and Adoption
A central element of the Company’s strategy is the CompuFlo Advisor Program, designed to accelerate hands-on physician experience, encourage repeat utilization, generate real-world reimbursement experience and identify physician champions who can support broader adoption.
Through September 2026, the Advisor Program generated over 180 epidural procedure feedback submissions across Medicare, commercial and other payer categories. This builds on an earlier evaluation involving 145 epidural procedures across seven U.S. states, where 99.3% of respondents reported CompuFlo was easy to use and all participating physicians indicated they would recommend the technology to colleagues.
The Company believes this growing base of physician experience can provide an important foundation for developing reference accounts, physician advocates and repeat utilization as commercial coverage expands.
Reimbursement Creates a Framework for Commercial Expansion
Milestone has also established an important reimbursement foundation for CompuFlo-guided procedures.
Healthcare providers currently have access to Medicare payment of approximately $325 per procedure under CPT® Category III code 0777T in the Novitas and First Coast jurisdictions. The Company is concentrating its commercial resources within these reimbursed markets while expanding activity within Palmetto and pursuing additional Medicare and commercial payer opportunities. Milestone has partnered with Avania Medical LLC for reimbursement and market-access support to help providers navigate reimbursement and support broader adoption.
The Company’s strategy is to establish utilization in markets where reimbursement is available, develop reference accounts and physician champions, and use those experiences to support expansion into additional jurisdictions.
Expanded Commercial Infrastructure Extends Market Coverage
Milestone has significantly expanded its commercial infrastructure to extend coverage. The organization now includes three dedicated medical sales professionals, approximately 15 sales consultants, three distribution partners, clinical and reimbursement support, physician advisors and key opinion leaders, with additional resources being added to expand coverage across other MAC jurisdictions.
This broader field organization is designed to reach key care settings including interventional pain practices, multisite physician groups, ambulatory surgery centers, hospitals and academic medical centers. The Company is pursuing a focused commercial model intended to combine direct sales resources, distribution partners, physician education, reimbursement support and clinical expertise.
“We are building commercial infrastructure around utilization rather than simply device placement,” said Mr. Hines. “The objective is to support physicians through the adoption process, help establish successful reference accounts and create the infrastructure needed to replicate that success across additional markets.”
Clinical Evidence Supporting Broader Utilization
Clinical validation continues in parallel with commercial expansion. CompuFlo has been evaluated or utilized at more than 40 universities, academic medical centers and teaching hospitals worldwide.
A recent 79-patient peer-reviewed University of Texas Medical Branch study associated CompuFlo-guided epidural access during spinal cord stimulator implantation with approximately a 91% reduction in the adjusted odds of composite complications compared with conventional loss-of-resistance techniques.
Additional research is underway, including a University of Minnesota study evaluating CathCheck® against epidurography for confirmation of epidural catheter placement, targeting approximately 50 participants. The Company believes continued clinical research can support broader utilization across pain management, neuromodulation, obstetric and other epidural procedures.
Physician Education and Market Development
The Company is also increasing physician awareness and market recognition through participation in leading pain and neuromodulation meetings, including NANS, ASPN, FSIPP, ISPN and other regional and international conferences, together with webinars, physician education and direct engagement with key opinion leaders.
These activities are intended to complement the Company’s commercial and clinical initiatives by increasing physician familiarity with CompuFlo and creating additional opportunities for hands-on evaluation and adoption.
International Market Development Expands Growth Opportunities
Internationally, Milestone is advancing market-development activities in Italy, Chile and Qatar, while evaluating additional opportunities across Europe, Latin America, the Middle East and Asia. The Company is pursuing international expansion through local distributors, physician champions, clinical education and targeted conference participation.
Milestone intends to apply the same general commercialization framework internationally: identify appropriate reimbursement and market-access pathways, establish physician experience and reference accounts, support clinical education and develop local commercial capabilities.
Positioned to Scale Utilization and Recurring Revenue
Mr. Hines concluded, “We have moved beyond establishing the building blocks of the CompuFlo medical business and are now focused on scaling the platform we have built. Physician adoption is expanding, reimbursement pathways are developing, our commercial organization is materially broader, and a growing body of clinical experience and evidence is supporting the technology.
“Our objective is to increase utilization, convert physician experience into recurring procedure volume and disposable revenue, expand our presence in reimbursed U.S. markets, and replicate that model across additional U.S. and international markets. As we continue to build the clinical and utilization evidence around CompuFlo, we are also working toward the longer-term opportunity to support a future transition of CPT 0777T from Category III to Category I.
“We believe the opportunity ahead is not simply to place more devices, but to establish CompuFlo as a repeat-use technology embedded in everyday clinical practice. The infrastructure we are putting in place today is designed to support that objective and create a scalable medical business with increasing recurring revenue potential.”
About Milestone Scientific Inc.
Milestone Scientific Inc. is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2025. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason. Coding and payment decisions are determined solely by providers and payers based on applicable laws and policies. Any potential Category I designation is determined solely by the American Medical Association and is not guaranteed. Providers remain responsible for compliance with all applicable billing, coding, and regulatory requirements. Forward-looking case submission expectations, reimbursement targets, and revenue estimates referenced herein are based on current program enrollment, advisor commitments, and historical payer activity, and are subject to change based on clinical scheduling, payer processing timelines, regulatory developments, and other factors. There can be no assurance that Category I designation, targeted reimbursement levels, or projected revenue levels will be achieved. This release also contains forward-looking statements regarding the development, capabilities, adoption, timing and expected benefits of Milo and Milestone’s broader artificial intelligence strategy, and the anticipated impact of the Company’s distribution agreement with Red One Medical, which does not guarantee contract awards, product evaluations, purchase orders or adoption by any federal agency or healthcare facility.
Contact:
HAYDEN IR:
James Carbonara
(646)-755-7412
james@haydenir.com
Brett Maas
(646) 536-7331
brett@haydenir.com
